The POCT market is large and has enjoyed sound growth. From 2008 to 2018, the sales volume of the global POCT market doubled, with an average annual compound growth rate of 7.5%. The global POCT sales volume in 2021 was $31.5 billion.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Bosch Healthcare Solutions has obtained CE-IVDR marking for its Vivalytic Bacterial Meningitis PCR test running on the company's fully automated Vivalytic analysis platform.

Revvity, Inc. (NYSE: RVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testosterone levels, marking a significant advancement in diagnostic capabilities for androgen disorders.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its whole slide imaging system, Roche Digital Pathology Dx, has received an additional 510(k) clearance from the United States Food and Drug Administration (FDA). This clearance modifies the one Roche received on June 14, 2024 for Roche Digital Pathology Dx, which includes the VENTANA DP 200 slide scanner, Roche's digital pathology workflow software and a display, and now adds the VENTANA DP 600 slide scanner.

Danaher Diagnostics LLC and Danaher Ventures LLC, two subsidiaries of Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology innovator, announced today that they have formed an investment partnership with Innovaccer Inc., a leading healthcare artificial intelligence (AI) company.

Shanghai announced on Wednesday to encourage wholly foreign-invested hospitals to be established in the municipality's key economic zones, areas where the biopharmaceutical industry clusters, and downtown districts with a high concentration of expat residents.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2024 and preliminary cash balance.

Roche (ROG.S), opens new tab on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics (PSTX.O), opens new tab, a specialist in complex immune cell therapies to treat several types of blood cancer.

OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that The Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA) has approved a labeling change to the OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range to include individuals 14 years of age and older for the OraQuick® HIV Self-Test. Previously the test was approved for use in those 17 and older.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has partnered with Genomics England to support the delivery of the Generation Study.

Gastric cancer is a common gastrointestinal carcinoid tumor, with the sixth highest incidence and second highest mortality rate among tumors.